
Herantis Pharma Investor Relations Material
Latest events

H2 2024
Herantis Pharma
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Herantis Pharma
Access all reports
Herantis Pharma Oyj is a Finnish biotechnology company focused on developing disease-modifying therapies for neurodegenerative diseases, particularly Parkinson's disease. The company's lead program centers around HER-096, a small synthetic chemical designed to mimic the activity of cerebral dopamine neurotrophic factor (CDNF). This treatment aims to address the progression of Parkinson's by protecting neurons and enhancing their function. The company is headquartered in Espoo, Finland, and its shares are listed on the Helsinki Stock Exchange.
Key slides for Herantis Pharma


Company Presentation
Herantis Pharma


Company Presentation
Herantis Pharma
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
HRNTS
Country
🇫🇮 Finland